-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...

-The Telegraph The government today dug out a 2006 verdict to argue that the Supreme Court was against auction of coal blocks as law minister Salman Khurshid questioned the presumptive revenue loss of Rs 1.86 lakh crore in the allocation of 57 blocks. Congress spokesperson Manish Tewari, who addressed a joint media conference with Khurshid, read out the verdict that had nullified the NDA government’s plan for e-auction of coal blocks. The verdict...

-The Hindu The debate on the pros and cons of genetically engineered/modified crops is universal. In India, in the face of vociferous protests, the controversy has only deepened leading to a moratorium on cultivation of Bt Brinjal crop — the first GM food crop sought to be commercialised. Gargi Parsai spoke to Basudeb Acharia, Chairman of the Parliamentary Standing Committee on Agriculture, on its new report, “Cultivation of Genetically Modified Food...

-PTI The Goa government has decided to implement stringent regulations on the mining industry in the state from August 15 onwards, with an aim to curtail unregulated and illegal mining in the state. Directorate of Mines and Geology in its letter to the association of mine owners, exporters and barges (ship carrying ore) owners has asked them to adhere to the new regulations, failing which strict action is prescribed in the notification. As...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...